Axogen, Inc. reported first‑quarter 2026 revenue of $61.5 million, up 26.6% from $48.6 million in the same period a year earlier. The company posted a net loss of $19.6 million, a widening of the GAAP loss compared with the $3.8 million loss reported in Q1 2025, but the adjusted earnings per share of $0.07 matched the consensus estimate of $0.07, reflecting disciplined cost management amid a higher mix of the biologic Avance product.
Gross margin expanded to 75.2% from 71.9% in Q1 2025, driven by a shift toward higher‑margin biologic products and improved operational leverage as sales volumes grew. The margin lift offsets the higher unit cost of Avance expected in the second half of 2026, which management anticipates will be mitigated by manufacturing efficiencies in 2027.
Management reiterated its 2026 revenue guidance, maintaining a minimum 20% growth target that translates to approximately $270 million in full‑year revenue. The company also reaffirmed its gross margin range of 74% to 76% and its expectation to be free‑cash‑flow positive for the year, underscoring progress in transitioning to a biologic‑based business model and the impact of a recent equity raise that eliminated term debt.
The results come on the heels of the December 2025 FDA approval of Avance Nerve Graft, Axogen’s first biologic therapeutic for peripheral nerve discontinuities. The approval positions the company to capture a larger share of the $5.6 billion peripheral nerve repair market, strengthen pricing power, and expand payer coverage, all of which contributed to the revenue beat and margin improvement.
"We are pleased with our first‑quarter revenue performance and the progress we're making across each of Axogen's strategic plan priorities. We delivered strong growth across all of our target markets, reinforcing the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our financial guidance and continue advancing our strategic objectives for 2026," said President and CEO Michael Dale.
The market reacted positively to the earnings, with analysts noting the revenue beat, the guidance raise, and the margin expansion as indicators of strong execution and confidence in the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.